Literature DB >> 19182738

Management of atrial fibrillation in the elderly.

W S Aronow1.   

Abstract

Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, diltiazem, or verapamil may be administered to slow immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds which are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in older patients, ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiar-rhythmic drugs. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should be treated with aspirin 325 mg daily.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19182738

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  7 in total

1.  95-year-old woman with sudden-onset dyspnea.

Authors:  Muaz M Abudiab; Olufunso W Odunukan; William K Freeman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

Review 2.  Evidence-based practice method of integrative Chinese and Western medicine based on literature retrieval through PICO question and complementary and alternative medicine topics.

Authors:  Xiu-feng Yan; Qing Ni; Jun-ping Wei; Hao Xu
Journal:  Chin J Integr Med       Date:  2010-11-26       Impact factor: 1.978

Review 3.  Invasive Management of Atrial Fibrillation and the Elderly.

Authors:  Sandeep M Patel; Samuel J Asirvatham
Journal:  J Atr Fibrillation       Date:  2010-08-23

4.  Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion.

Authors:  Wu Deng; Laurie Farricielli
Journal:  BMJ Case Rep       Date:  2013-09-16

Review 5.  Use of Inotropic Agents in Treatment of Systolic Heart Failure.

Authors:  Sohaib Tariq; Wilbert S Aronow
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

6.  Chinese medicine shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial.

Authors:  Yunfang Liu; Ning Li; Zhenhua Jia; Feng Lu; Jielin Pu
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629

Review 7.  Managing atrial fibrillation in the very elderly patient: challenges and solutions.

Authors:  Nikolaos Karamichalakis; Konstantinos P Letsas; Konstantinos Vlachos; Stamatis Georgopoulos; Athanasios Bakalakos; Michael Efremidis; Antonios Sideris
Journal:  Vasc Health Risk Manag       Date:  2015-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.